advanced carcinoid

Related by string. * advancing . Advancing . ADVANCED . advancer . AdvancED . Advanced : Advanced Micro Devices . rival Advanced Micro . Advanced Metering Infrastructure AMI . Advanced Placement courses . Patriot Advanced Capability . advanced / Carcinoid : carcinoid . carcinoid tumors . carcinoid cancer . carcinoid syndrome diabetes . syndrome carcinoid syndrome . carcinoid syndrome * *

Related by context. All words. (Click for frequent words.) 73 cancer neuroendocrine tumor 72 lintuzumab SGN 71 relapsed multiple myeloma 70 relapsed leukemia 70 measurable tumor regressions 70 Atiprimod 69 oral picoplatin 69 CYT# potent vascular disrupting 69 evaluating picoplatin 69 metastatic renal cell 69 systemic anaplastic large 69 VEGFR2 inhibitor 69 hematological cancers notably 69 essential thrombocythemia ET 68 Annamycin 68 Phase #b/#a clinical 68 alvespimycin 68 ELACYT 68 recurrent glioblastoma multiforme 68 Panzem R NCD 67 relapsed MM 67 relapsed refractory multiple myeloma 67 refractory NSCLC 67 recurrent metastatic ovarian cancer 67 unresectable Stage III 67 OMP #R# 67 PNP inhibitor 67 Bezielle 67 indolent follicular non 67 forodesine 67 dasatinib Sprycel ® 67 IAP inhibitor 67 compound INCB# 67 Phase 2b Clinical Trial 67 chemosensitizer 67 receiving chemoradiation therapy 67 refractory chronic lymphocytic 67 sarcoma melanoma 66 2 methoxyestradiol 66 carcinoma mCRC 66 mitoxantrone plus 66 progressive metastatic prostate 66 BCG refractory carcinoma 66 metaglidasen 66 Exherin TM 66 Fibrillex TM 66 AAG geldanamycin analog 66 pralatrexate injection folate analogue 66 de novo kidney transplant 66 oral prodrug 66 targeted radiotherapeutic 66 orally administered inhibitor 66 Troxatyl 66 Meets Primary Endpoint 66 Ribavirin causes 66 acetonide FA 66 sorafenib tablets 66 metastatic castration resistant 66 Brentuximab Vedotin SGN 66 Frozen Shoulder syndrome Adhesive 66 tumors GIST 66 metastatic colorectal 66 selective angiogenic kinase inhibitor 65 Archexin 65 MKC# MT 65 Epothilone D 65 IRX 2 65 trastuzumab Herceptin R 65 intravenous belinostat 65 plus prednisone prednisolone 65 Personalized Immunotherapy 65 MGd 65 catheter occlusion 65 XL# anticancer compounds 65 Panzem R 65 GVAX Immunotherapy 65 huC# DM4 65 trial evaluating PRX# 65 castration resistant hormone refractory 65 FOLOTYN ® 65 demonstrated antitumor activity 65 FUSILEV enhances 65 rindopepimut 65 HER2 positive metastatic breast 65 triggers apoptosis programmed 65 delivers fluocinolone acetonide FA 65 carcinoma HCC 65 leukemia AML 65 LymphoStat B belimumab 65 ALN VSP Phase 65 BENLYSTA TM 65 Voreloxin 65 Aflibercept 65 pancreatic colon 65 ThermoDox R 65 R sorafenib tablets 65 cell lymphoma CTCL 65 ATRA IV 65 steroid refractory 64 Peginterferon alfa 2b 64 including eniluracil ADH 64 Initiates Phase II 64 Nicole Onetto MD 64 phase IIb clinical 64 cutaneous T 64 gastrointestinal mucositis 64 Cloretazine ® 64 Omacetaxine 64 OHR/AVR# 64 unresectable tumors 64 Cutaneous T 64 relapsing remitting MS RRMS 64 myelofibrosis polycythemia vera 64 taxane chemotherapy administered 64 zanolimumab 64 Phase Ib clinical trials 64 Alocrest 64 CEQ# 64 anti PlGF 64 lenalidomide Revlimid R 64 sapacitabine CYC# 64 Genasense oblimersen sodium Injection 64 transplantation HCT 64 IMA# 64 refractory acute myeloid 64 novel tubulin binding 64 metastatic renal 64 develop HBV reactivation 64 non splenectomized 64 oral nucleoside analogue 64 novel VDA molecule 64 gastrointestinal stromal 64 myelodysplastic myeloproliferative diseases 64 bladder ovarian 64 metastatic bladder 64 Myelodysplastic Syndrome MDS 64 unique alkylating agent 64 biliary tract cancer 64 resistant hormone refractory 64 SNT MC# 64 modified glutathione analog 64 CDK cyclin dependent 64 MAGE A3 ASCI 64 PSMA ADC 64 TKB# 64 deforolimus 64 INSPIRE Trial Phase III 64 adult chronic ITP 64 Hsp# Inhibitor 64 receptor tyrosine kinase inhibitor 64 stage IIIb IV 64 Vicinium TM 64 oral isoform selective HDAC 64 CD# antibody [002] 64 recurrent NSCLC 64 drug pipeline TAFA# 64 CR# vcMMAE 64 PI3K/Akt pathway inhibitor 64 induced macular edema 64 YONDELIS 64 refractory AML 64 TTF Therapy 64 refractory indolent non 64 relapsed Acute Myeloid 64 Begins Dosing 64 dependent kinase inhibitor 64 Phase #/#a trial 64 CD# CEA 64 Pivotal Phase III 63 5 fluorouracil leucovorin 63 Severe VOD 63 PEGylated Fab fragment 63 recombinant PSMA vaccine 63 keloid scarring 63 IgG1 monoclonal antibody 63 nucleoside analog 63 5 FU leucovorin 63 MCSP respectively 63 sirtuin inhibitor program 63 Dacogen injection 63 MDS AML 63 CYT# vascular disrupting 63 Antitumor Activity 63 HRPC 63 rALLy 63 unresectable locally advanced 63 multiple myeloma MM 63 LHRH receptor positive 63 AEG# 63 anthracycline taxane 63 oral ridaforolimus 63 personalized cellular immunotherapy 63 Xanafide 63 Aplidin 63 Uricase PEG 63 Tumour Vascular Disrupting Agent 63 metastatic pancreatic 63 CD4 monoclonal antibody 63 metastatic malignant 63 doublet chemotherapy 63 initiated Phase Ib 63 INCB# [001] 63 Cloretazine 63 ATL# [001] 63 R rilonacept Injection 63 opioid induced bowel dysfunction 63 paclitaxel Taxol R 63 Randomized Phase II 63 refractory CLL 63 compound ISA# 63 hyperphenylalaninemia HPA due 63 alkylating agent 63 Elotuzumab 63 monoclonal antibody IgG1 Mab 63 severe oral mucositis 63 vaccine GMK 63 Proxinium TM 63 axitinib 63 alpha folate receptor 63 Prednisone Against Refractory 63 metastatic GIST 63 topical antifungal product 63 dimebon latrepirdine 63 Fludarabine 63 CCR9 antagonist 63 Kamada AAT 63 Telik logo TELINTRA 63 previously untreated follicular 63 kidney urologic 63 Completes Patient Enrollment 63 registrational trial 63 metastatic gastric 63 Sapacitabine 63 Relapsed Refractory 63 neutropenia dehydration dyspnea 63 Phase 1b clinical trials 63 severe hypercholesterolemia 63 docetaxel Taxotere ® 63 Ophena TM 63 corticosteroid dexamethasone 63 IMiDs 63 leading oral taxane 63 D aspartate NMDA receptor 63 relapsed acute myelogenous 63 MKC# 63 refractory gout 63 SPRYCEL ® 63 elacytarabine 63 Hedgehog Pathway Inhibitor 63 Crofelemer budesonide foam 63 Ph + acute lymphoblastic 63 evaluating T DM1 63 class mGluR5 inhibitor 63 elotuzumab 63 hypoxia activated prodrug 63 refractory colorectal cancer 63 GVAX ® 63 Amigal TM 63 metastatic colorectal carcinoma 63 ara C 63 Forodesine HCl 63 Amgen Neulasta ® 63 PXD# 63 evaluating intravenous picoplatin 63 IL# PE#QQR 63 arsenic trioxide injection 63 HGS ETR1 mapatumumab 63 Romiplostim 63 heavily pretreated 63 steroid refractory GvHD 63 expressing metastatic colorectal 63 rALLy clinical trial 63 Amgen Neulasta R 63 metastatic hormone refractory 63 advanced metastatic prostate 63 investigational monoclonal antibody 63 Investigational Treatment 63 pan histone deacetylase 63 nilotinib Tasigna ® 63 Phase IIb Clinical Trial 63 R#/MEM # 62 Genasense ® oblimersen 62 huN# DM1 62 ® bortezomib 62 commercialize deforolimus 62 Chronic Lymphocytic Leukemia CLL 62 Pruvel TM 62 midstage clinical 62 pancreatic carcinoma 62 allogeneic bone marrow 62 delay bone metastases 62 Kit CD# positive 62 HCD# [002] 62 Virulizin ® 62 3 registrational trial 62 prokinetic agent 62 Fx #A 62 budesonide foam 62 tumor lysis syndrome 62 BENLYSTA belimumab 62 achieved CCyR 62 TACI Ig 62 Initiates Enrollment 62 relapsed SCLC 62 HGS ETR1 62 MyVax R 62 Cerebril TM 62 antiangiogenesis therapies 62 polycythemia vera essential thrombocythemia 62 BENLYSTA ® 62 BRIM2 62 TNFerade ™ 62 CIMZIA TM 62 adhesion molecule EpCAM expressing 62 humanized therapeutic 62 herpetic keratitis 62 familial amyloidotic polyneuropathy FAP 62 Vascular Disrupting Agent 62 OvaRex R 62 albiglutide 62 Traficet EN 62 mouse xenograft models 62 metastatic carcinoid 62 markets Testim ® 62 R Bortezomib 62 cisplatin gemcitabine 62 AKT inhibitor 62 intravesical infusion therapy 62 Cloretazine R VNP#M 62 generation Hsp# inhibitor 62 imetelstat GRN#L 62 paclitaxel Taxol ® 62 ® lenalidomide 62 untreated metastatic colorectal 62 PEG SN# 62 cMET 62 RANK Ligand inhibitor 62 Microplasmin 62 hormone refractory metastatic prostate 62 Metastatic Melanoma 62 Daclizumab 62 non nucleoside inhibitor 62 non myeloid malignancies 62 ADAGEN 62 hypereosinophilic syndrome 62 standard chemotherapy regimen 62 development peramivir neuraminidase 62 Combination REOLYSIN R 62 potent triglyceride lowering 62 novel synthetic PEGylated 62 Granted Orphan Drug 62 Phase III Pivotal 62 Phase IIb clinical trials 62 refractory metastatic 62 Phase 2b Trial 62 Solazed TM 62 sunitinib malate 62 JAK1 62 vitreoretinal disorders 62 GRNOPC1 contains 62 Vidaza ® 62 developing Bicifadine serotonin 62 TLR7 agonist 62 Refractory Hodgkin Lymphoma 62 octreotide implant 62 VELCADE melphalan 62 antibody MAb 62 TRAIL receptor antibodies 62 6 sulfatase 62 Dosa suffers 62 advanced metastatic renal 62 esophageal candidiasis 62 TO AVOID PREGNANCY WHILE 62 recurrent glioblastoma 62 NU# direct 62 Zenvia TM 62 PEGylated irinotecan 62 relapsed AML 62 Evoltra ® 62 accumulate preferentially 62 metastatic CRC 62 Malignant Glioma 62 Phase Ib IIa 62 irinotecan doxorubicin oxaliplatin paclitaxel 62 Enzastaurin 62 ATC ovarian cancer 62 candidates Azedra TM 62 Glioblastoma Multiforme 62 drug ISA# 62 GRN# 62 Castration Resistant Prostate Cancer 62 Thiarabine 62 gemcitabine Gemzar ® 62 non constipating irritable 62 taxane chemotherapy 62 E1 INT TM 62 formerly LymphoStat B 62 EGFR expressing metastatic colorectal 62 Budesonide foam crofelemer 62 radiation chemoradiation 62 TELINTRA 62 Tezampanel 62 dose escalation phase 62 generation DACH Platinum 62 CCX# B 62 Diffuse Large B 62 Sudhir Agrawal D.Phil 62 GALNS N acetylgalactosamine 62 deep venous thromboses 62 Ceflatonin R 62 advanced HER2 positive 62 unresectable stage 62 INCB# [003] 62 idiopathic thrombocytopenic purpura ITP 62 TBC# 62 refractory cutaneous T 61 enzastaurin 61 plus prednisone 61 SUTENT ® 61 oral TLR7 agonist prodrug 61 Oral Calcitonin 61 erlotinib Tarceva ® 61 Tramiprosate ALZHEMED TM 61 PEGylated docetaxel 61 galiximab 61 allogeneic HSCT 61 RhuDex TM 61 Phase IIb Trial 61 evaluating tivozanib 61 peptidic compound 61 drug GAP #B# 61 Pemetrexed 61 leukemia ALL 61 aplastic anemia AA 61 TTR amyloidosis 61 lymphoid malignancies 61 atrial fibrillation budiodarone ATI 61 IIa trial 61 Ovitrelle R Serostim 61 castrate resistant prostate cancer 61 docetaxel Taxotere R 61 selective modulator 61 BrachySil TM 61 gemcitabine cisplatin 61 Irinotecan 61 infectious diseases autoimmune 61 superficial bladder cancer 61 substantially excreted 61 TELINTRA R 61 Completes Enrollment 61 ovarian prostate 61 Advanced Renal Cell 61 leukemia CLL 61 psoriasis rheumatoid arthritis 61 EGFr humanized monoclonal antibody 61 developing adecatumumab 61 Phase Ib II 61 Cannabinor 61 bone marrow reticulin deposition 61 JAK2 Inhibitor 61 EVIZON TM squalamine lactate 61 refractory multiple myeloma 61 Telintra 61 phase Ib 61 Phase Ib study 61 virus HCV protease inhibitor 61 R roscovitine CDK cyclin 61 Presents Positive 61 Zevalin R Ibritumomab 61 dextromethorphan quinidine 61 lung pancreatic 61 histone deacetylase HDAC inhibitor 61 lymphoma CTCL 61 AQ4N 61 Vicriviroc 61 papillary renal cell carcinoma 61 ALN HPN 61 chronic eosinophilic leukemia 61 thalidomide Thalomid 61 Achieves Primary Endpoint 61 allogeneic hematopoietic stem cell 61 Romidepsin 61 generation PNP inhibitor 61 clinical trials dacetuzumab SGN 61 RhuDex R 61 DNA methyltransferase inhibitors 61 pan HDAC inhibitor 61 Azedra TM 61 Newly Diagnosed Multiple Myeloma 61 acyclovir Lauriad R 61 dacarbazine DTIC 61 Hormone Refractory Prostate Cancer 61 PLX STROKE targeting 61 Seliciclib 61 forodesine hydrochloride 61 HGS ETR2 61 Receives Orphan Drug Designation 61 Alessandro Riva 61 dirucotide MBP# 61 refractory metastatic colorectal cancer 61 clinical trials Archexin 61 glufosfamide 61 forodesine purine nucleoside phosphorylase 61 cell carcinoma RCC 61 Phase Ib clinical 61 alfa 2a 61 SinuNase TM 61 VNP#M 61 II Clinical Trial 61 sunitinib Sutent 61 Allovectin 7 61 nephropathic cystinosis cystinosis 61 Hepatocellular Carcinoma HCC 61 agonistic human 61 active AKT inhibitor 61 CD# expressing 61 interferon gamma 1b 61 MKC# MKC# PP 61 Trofex 61 Bayer HealthCare Onyx Pharmaceuticals 61 CIMZIA ™ 61 sodium Injection 61 follicular Non Hodgkin 61 Phase IIIb clinical 61 veltuzumab 61 Syncria albiglutide 61 gastrointestinal stromal tumor GIST 61 Panzem NCD 61 small molecule thrombopoietin 61 Initiates Clinical Trial 61 Vascugel 61 oxypurinol 61 Behcet uveitis 61 multi kinase inhibitor 61 EGFR expressing mCRC 61 Glufosfamide 61 Follicular Lymphoma 61 generation purine nucleoside 61 Lupus nephritis 61 reduce serum phosphate 61 Myelofibrosis 61 recurrent metastatic 61 novel topoisomerase 61 systemically administered 61 candidate XP# 61 liposomal formulation 61 E2F Decoy 61 novel nucleoside analog 61 non metastatic osteosarcoma 61 clinical trials SGN 61 cyclophosphamide chemotherapy 61 TNF blocker therapy 61 MGCD# [001] 61 urocortin 2 61 Alzhemed TM 61 gemcitabine chemotherapy 61 hA# 61 albiglutide currently 61 K ras mutations 61 CTAP# 61 untreated metastatic pancreatic 61 drugs FUSILEV 61 homozygous familial hypercholesterolemia 61 estramustine 61 following fluoropyrimidine oxaliplatin 61 receiving VELCADE 61 pharmacogenomic translational research 61 Epratuzumab 61 cutaneous T cell 61 azilsartan medoxomil 61 myocardial infarction ventricular fibrillation 61 non hodgkin lymphoma 61 MPS IVA 61 Chemophase 61 mRCC 61 oral ghrelin agonist 61 telaprevir dosed 61 oral dihydropyrimidine dehydrogenase DPD 61 recurrent GBM 61 diagnosed GBM 61 Provectus Pharmaceuticals specializes 61 Acute Myeloid Leukemia AML 61 oral clodronate 61 trastuzumab Herceptin ® 61 GALNS 61 TRIOLEX HE# APOPTONE HE# 61 docetaxel Taxotere 61 adalimumab Humira 61 Aztreonam lysine 61 EndoTAGTM 1 61 Receives Fast Track 61 BZL# 61 Vandetanib 61 Inc. www.micromet inc.com 61 monoclonal antibody conjugated 61 diarrhea predominant irritable 61 efaproxiral 61 recurrent genital herpes 61 pomalidomide 61 deCODE ProstateCancer TM 61 chronic thromboembolic pulmonary 61 FOLFOX chemotherapy 61 leukemia APL 61 CCR5 mAb 61 vascular occlusive diseases 61 markets HP Acthar 61 Triapine R 61 occlusion PAO 61 refractory acute lymphoblastic 61 LEP ETU 61 Pivotal Phase 61 ErbB2 positive 61 tanespimycin 61 GVAX R 61 Orphan Drug status 61 Tarceva TM 61 NPC 1C 61 Phase IIb trials 61 interferon beta 1a infertility 61 dosing cohort 61 CTAP# Capsules 61 Relapsed Refractory Multiple Myeloma 61 essential thrombocythemia 61 please visit http:/www.avastin.com 61 Insulin PH# 61 R Saizen R 61 Fovea Pharmaceuticals subsidiary 61 inhaled liposomal ciprofloxacin 61 Acute myelogenous leukemia 61 toenail onychomycosis 61 pseudobulbar affect PBA 61 assessing T DM1 61 refractory myeloma 61 vapreotide acetate 61 Submits Response 60 docetaxel chemotherapy 60 radiation sensitizer 60 Campath alemtuzumab 60 secondary hyperparathyroidism 60 oral proteasome inhibitor 60 SNT-MC#/idebenone 60 Spiro Rombotis President 60 UCB www.ucb group.com 60 metastatic liver 60 Steven R. Deitcher 60 advanced medullary thyroid 60 lesinurad 60 novel antimitotic agent 60 oral chemotherapeutic agent 60 injectable investigational 60 epithelial tumors 60 Ceflatonin 60 TRO# 60 Intravenous CP 60 cetuximab Erbitux R 60 BRAF mutant 60 LymphoStat B TM 60 metastatic HER2 negative 60 phase IIb trial 60 ALN TTR 60 tubulin inhibitor 60 Familial Adenomatous Polyposis FAP 60 ThermoDox ® 60 Initiate Clinical Trial 60 cisplatin chemotherapy 60 sapropterin dihydrochloride 60 developing Zerenex TM 60 class anticancer quinolone 60 Tasimelteon 60 castrate resistant 60 Testosterone MDTS ® 60 evaluating mipomersen 60 taxane refractory 60 vaccines oncolytic virus 60 MAXY alpha 60 infectious diseases autoimmune diseases 60 IMiDs ® 60 neuropathy sparing 60 JAK#/JAK# inhibitor CYT# 60 angiotensin analog 60 relapsed CLL 60 hematological malignancy 60 recurrent glioblastoma multiforme GBM 60 velafermin 60 ASG 5ME 60 Patient Enrollment 60 lorvotuzumab mertansine 60 pertuzumab 60 CA4P 60 myelofibrosis 60 HQK 60 factor TNF receptor 60 vinca alkaloid 60 iobenguane 60 Acute myeloid leukemia 60 TM pralatrexate injection 60 R lenalidomide 60 TNF Tumor Necrosis Factor 60 Trofex TM 60 CML CP 60 alanine transaminase ALT 60 evaluating Actimmune 60 thetreatment 60 Exelixis XL# 60 Lixivaptan 60 Ostarine ™ 60 CLL SLL 60 OTC BB PVCT http:/www.pvct.com 60 dexamethasone Decadron 60 Infusion reactions 60 Golimumab 60 indolent NHL 60 Amrubicin 60 TOCOSOL Camptothecin 60 tafamidis 60 compound PMX # 60 idiopathic thrombocytopenic purpura 60 complement inhibitor eculizumab 60 Anthracycline 60 NeoLipid R 60 PDX pralatrexate 60 Folfox 60 Solazed 60 imatinib Gleevec ® 60 potent CYP#A# inhibitors 60 LHRH agonists 60 Phase III Trial 60 Testosterone MDTS R 60 adecatumumab 60 rhIGF-I/rhIGFBP-3 60 ZACTIMA 60 ZEVALIN ® 60 Abiraterone acetate 60 SinuNase ™ 60 debilitating complication 60 pancreatic prostate 60 Initiates Phase III 60 ThermoDox ® clinical 60 telomerase therapeutic 60 Major Depressive Disorder MDD 60 Xelox 60 Gel repository corticotropin injection 60 thrombin inhibiting aptamer 60 refractory Hodgkin 60 Soliris TM eculizumab 60 Vitrasert R 60 apoptosis inducer 60 undergoing hematopoietic stem 60 sodium thiosulfate STS 60 generation URAT1 inhibitor 60 JAK inhibitor 60 brivanib 60 Panzem 60 polysaccharide polymer 60 antibody MT# 60 SUPPRELIN R LA 60 ACTEMRA TM 60 generation geldanamycin analog 60 investigational oral inhibitor 60 Host Disease 60 gefitinib Iressa 60 gastro intestinal inflammation 60 refractory acute promyelocytic 60 IMC #B 60 OncoVEX GM CSF 60 NEBIDO R 60 recurrent glioma 60 ALN PCS 60 overactive bladder AA# 60 ASONEP TM 60 advanced compound INCB# 60 Zenvia ™ 60 Zerenex 60 DIFICID ™ 60 KRN# 60 Phase Ib 60 Gliadel Wafer 60 palonosetron hydrochloride Injection Dacogen 60 metastatic castrate resistant 60 humanized interleukin 6 60 vaginal lidocaine product 60 lymphoma multiple myeloma 60 lumiliximab 60 lead compound ISA# 60 neovascular diseases 60 AVASTIN 60 Presents Preclinical 60 Initiate Phase 60 farletuzumab 60 primary immunodeficiency PI 60 cetuximab Erbitux 60 ganetespib 60 Temodar ® 60 anti amnesic 60 Tovaxin TM 60 Phase 1b 60 aflibercept VEGF Trap 60 novel emulsion formulation 60 targeting CD# 60 myeloproliferative disorders 60 Serostim ® 60 Advanced Melanoma 60 autologous hematopoietic stem cell 60 Elagolix 60 mertansine 60 SUTENT 60 Darinaparsin 60 OTC BB PVCT 60 events thrombocytopenia neutropenia 60 systemic ALCL 60 VAPRISOL 60 MNTX 60 Laquinimod 60 gamma secretase inhibitor 60 thrombotic disorders 60 Ocrelizumab 60 ixabepilone 60 Randomized Phase 60 website www.celsion.com 60 severe hypersensitivity reactions 60 Soft Tissue Sarcoma 60 lintuzumab 60 sorafenib Nexavar 60 ZOLINZA 60 Mipomersen 60 pegfilgrastim 60 EFAPROXYN 60 unfavorable cytogenetics 60 cause mesothelioma asbestosis 60 alemtuzumab Campath 60 Previously Treated 60 hematological diseases 60 omacetaxine mepesuccinate 60 EGFr expressing mCRC 60 beta 1a 60 relapsed acute lymphoblastic 60 dacetuzumab SGN 60 AGILECT R 60 memantine HCl 60 Metastatic Colorectal Cancer 60 Phase 2a Clinical Trial 60 next generation URAT1 60 eniluracil 60 product platforms AZX# 60 phase IIa clinical 60 R memantine HCl 60 signal transduction inhibitor 60 Atypical Hemolytic Uremic Syndrome 60 Hypertensive adverse reactions 60 ANYARA 60 GW# [003] 60 TKM ApoB 60 Aurora Kinase 60 Xeloda ® 60 Symadex 60 Initiates Phase 60 bile duct tumor 60 oxymorphone ER 60 Azacitidine 60 chronic myeloid 60 novel histone deacetylase 60 KIACTA ™ 60 Fast Track designations 60 dasatinib Sprycel 60 4SC AG ISIN DE# 60 #mg/m# [001] 60 CYC# 60 RESTORE CLI trial 60 seliciclib CYC# 60 Bortezomib 60 non porcine pancreatic 60 trial evaluating Prochymal 60 Lenocta 60 Sym# 60 familial hypercholesterolemia FH 60 mapatumumab 60 IMC A# 60 DCVax R 60 low dose cytarabine 60 EndoTAG TM -1 60 cirrhosis liver failure 60 Mitoxantrone 60 malignant ascites 60 Cytarabine 60 rituximab refractory 60 Pruvel ™ 60 remission induction 60 constipation OIC 60 Biogen Genentech 60 novel therapeutic antibodies 60 IMPACT DCM trial 60 oral FTY# 60 AA amyloidosis 60 iGVHD 60 Previously Untreated 60 Phase III Clinical Trial 60 CINQUIL 60 Neuvenge 60 Trastuzumab 60 PANVAC VF 60 Genasense ® 60 Aclidinium 60 Xcytrin R 60 haematological malignancies 60 Initiate Phase III 60 post operative ileus 60 treats paroxysmal nocturnal 60 fallopian tube cancers 59 sapropterin dihydrochloride Tablets 59 BRAF inhibitor 59 evaluating satraplatin 59 Curaxin CBLC# 59 EGFR mutation positive 59 leukemia lymphoma multiple myeloma 59 Pegloticase 59 Talabostat 59 PLK1 SNALP 59 triphendiol 59 GATTEX TM 59 5 FU capecitabine 59 Lupus Nephritis 59 BCR ABL inhibitor 59 cannabinor 59 Trial Evaluating 59 Pafuramidine 59 chemotherapy FOLFOX 59 taxane resistant 59 Reports Preclinical Data 59 HDAC Inhibitor 59 Philadelphia Chromosome Positive 59 non resectable 59 #mg BID [001] 59 esthesioneuroblastoma rare form 59 mGluR5 NAM 59 Azedra 59 IMiDs R 59 ulimorelin 59 chemotherapy induced neutropenia 59 tramiprosate Alzhemed TM 59 omecamtiv mecarbil formerly 59 advanced hepatocellular carcinoma 59 milatuzumab 59 pyrexia mucositis sepsis febrile 59 GvHD 59 haematologic malignancies 59 MyVax ® 59 lymphoid blast 59 #ME# 59 www.incyte.com 59 Eltrombopag 59 EGFr expressing metastatic colorectal 59 * olmesartan medoxomil 59 HuMax EGFr 59 ISTODAX 59 nonmyeloablative 59 Triapine 59 Acute myeloid leukemia AML 59 Novel Oral 59 pediatric acute lymphoblastic 59 malignant pleural mesothelioma MPM 59 adecatumumab MT# 59 TASKi2 59 Inc. ProMetic www.prometic.com 59 CRLX# 59 #I TM# 59 ADVEXIN p# therapy 59 lomitapide 59 Oxypurinol 59 CYP#A# CYP#D# 59 KNS # 59 OvaRex ® MAb 59 treatment naive genotype 59 metastatic sarcomas 59 Dendreon investigational 59 exocrine pancreatic insufficiency EPI 59 peripheral arterial occlusive disease 59 baminercept 59 recurrent malignant glioma 59 PAOD 59 dyslipidemia hypertension diabetes 59 Phase IIa trials 59 Ibritumomab Tiuxetan 59 Zemplar Capsules 59 small molecule Hedgehog 59 Prestara 59 stage IIIb 59 Zorbtive TM 59 Aloxi injection 59 maximally tolerated lipid lowering 59 Revlimid lenalidomide 59 XL# XL# XL# XL# 59 Acute Myelogenous Leukemia AML 59 HBeAg negative 59 cilengitide 59 rimonabant #mg/day 59 adriamycin 59 IMPDH inhibitor 59 Androxal TM 59 Successfully Completes Phase

Back to home page